A Clinical Approach to Integrative Care Solutions for OUD Treatment

Integrative care plays a key role in the clinical approach for OUD, enhancing support and treatment effectiveness for patients.

Educational Abstract: Integrative Evidence-Based Care for Opioid Use Disorder — How Chiropractic, Internal Medicine, and Functional Medicine Work Together

In this educational post, I present a comprehensive, first-person journey through the history, physiology, stigma, and modern treatment of opioid use disorder (OUD), grounded in the latest peer-reviewed research and clinical guidelines. I explain how different opioid classes interact with human neurobiology, why medications for OUD markedly lower mortality, and how motivational interviewing and harm reduction strategies improve engagement and safety. I also detail our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, collaborate under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Together, we integrate chiropractic care, internal medicine oversight, functional medicine, rehabilitation, and personal-injury-informed protocols to deliver precise, patient-centered, evidence-based OUD care. Throughout, I share clinical observations from my practice and referenced insights from leading researchers, ensuring the discussion aligns with current standards from SAMHSA, CDC, NIH/NIDA, ASAM, and major systematic reviews. SEO-focused headings and structured bullet lists support readability and navigation.

My Team, My Role, and Our Integrative Model

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In clinical practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, we use a multidisciplinary care model common to integrative and injury clinics: a physician-led, evidence-based framework that combines medical oversight, chiropractic care, functional medicine, rehabilitation, and behavioral supports.

• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933
• My credentials and role: Doctor of Chiropractic and Advanced Practice Registered Nurse/Family Nurse Practitioner, board-certified, with certifications in functional medicine and integrative care.
• Our integrated services:

• • Medical evaluation and supervision for OUD and co-occurring conditions
  • Evidence-based medications for OUD (MOUD) coordinated with internal medicine oversight
  • Functional medicine evaluation of root-cause drivers (gut-liver-brain axes, endocrine, mitochondrial dysfunction, inflammation)
  • Chiropractic care for pain modulation, autonomic regulation, and functional improvement, aligned with medical assessment to minimize opioid reliance
  • Rehabilitation and movement therapy to restore proprioception, biomechanics, and the neuromuscular patterns disrupted by chronic pain and substance use
  • Behavioral health referral and motivational interviewing for engagement and adherence
  • Personal injury-informed protocols recognizing medico-legal, pain, and psychosocial factors after trauma

Clinical observations from my practice help us tailor care plans to each patient’s physiology, circumstances, and goals. I routinely share clinical insights in public education on platforms such as:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Why I’m Writing This: A First-Person Educational Journey

The opioid landscape is complex and emotionally charged. Patients, families, and clinicians often struggle to reconcile pain management, addiction risk, and stigma. My purpose here is to synthesize state-of-the-art evidence and to show how a coordinated, multidisciplinary approach improves outcomes. I will:

• Summarize the history of opioids and treatment milestones.
• Explain opioid classes, potency relationships, and receptor pharmacology.
• Describe DSM-5 substance use disorder criteria and why behavior-based diagnostics matter.
• Debunk myths with evidence and frame stigma reduction as a clinical priority.
• Provide practical guidance on motivational interviewing, stages of change, and language choices.
• Review medications for opioid use disorder, their mechanisms, safety, and why they save lives.
• Integrate chiropractic care and functional medicine within a medically supervised OUD plan.
• Outline harm reduction tactics that protect patients and communities.
• Show how our clinic operationalizes these methods under internal medicine oversight.

The History of Opioids and Milestones in Treatment and Policy

Humanity’s relationship with opioids stretches across millennia. It has changed dramatically over the past two centuries as advances in chemistry, pharmacology, and public policy have continually reshaped both medical practice and societal attitudes.

Opioids are conventionally grouped into three categories according to their origin. Natural opioids, also called opiates, are extracted directly from the opium poppy (*Papaver somniferum*); the most familiar examples are morphine and codeine. Semi-synthetic opioids are produced by chemically modifying natural opiates; this group includes heroin (diacetylmorphine), oxycodone, and hydrocodone. Fully synthetic opioids are created entirely in the laboratory and include methadone and fentanyl.

The historical record begins as early as 3400 BCE, when the opium poppy was cultivated in Mesopotamia. By the classical period, Greek and Roman physicians were employing opium preparations for pain relief, and by the sixteenth century its use had expanded to the treatment of diarrhea. A decisive scientific breakthrough occurred in 1803 when morphine was isolated, introducing a potent and reliable analgesic that transformed clinical pain management. Codeine followed in 1832 and quickly became a cough suppressant. In 1874, chemists synthesized heroin from morphine; the compound was initially promoted with optimistic therapeutic claims before its high addiction potential became widely recognized. Methadone was synthesized in 1939 and later emerged as a cornerstone of opioid-use-disorder treatment. Fentanyl, developed in 1959, is roughly fifty times more potent than morphine; it revolutionized anesthesia yet later became a major contributor to overdose waves. Buprenorphine was discovered in 1966; as a partial agonist, it possesses a unique ceiling effect on respiratory depression that has made it especially valuable in treatment settings.

Parallel policy developments have steadily reframed the legal and clinical handling of opioids. The Harrison Narcotics Tax Act of 1914 criminalized non-medical opiate use and thereby altered both access and everyday medical practice. The Controlled Substances Act of 1970 established the modern scheduling system and gave the Drug Enforcement Administration oversight authority. The Narcotic Addiction Treatment Act of 1974 imposed federal regulation on methadone programs and formalized opioid-treatment protocols. The Drug Addiction Treatment Act (DATA) of 2000 opened the door to office-based buprenorphine prescribing through the X-waiver system. Subsequent legislation continued the expansion of access: the Comprehensive Addiction and Recovery Act (CARA) of 2016 authorized nurse practitioners and physician assistants to prescribe buprenorphine after specified training; the SUPPORT for Patients and Communities Act of 2018 broadened opioid-use-disorder treatment coverage within Medicare and Medicaid; and the Mainstreaming Addiction Treatment (MAT) Act of 2023 eliminated the X-waiver requirement, allowing any DEA-licensed clinician to prescribe buprenorphine consistent with their professional scope for Schedule III substances.

Taken together, these scientific and legislative shifts mark a gradual but decisive movement toward recognizing opioid-use disorder as a chronic medical condition rather than solely a criminal matter—an approach that aligns with contemporary addiction neuroscience and public-health principles (Substance Abuse and Mental Health Services Administration [SAMHSA], 2023; Centers for Disease Control and Prevention [CDC], 2024).

Understanding Opioid Potency, Pharmacology, and Risk

When weighing treatment decisions, clinicians rely on morphine milligram equivalents (MME) together with receptor dynamics. Absolute potency is useful, yet receptor behavior and pharmacokinetics ultimately determine clinical risk.

Relative potencies illustrate the range of activity. Tramadol is assigned approximately 0.1 MME, codeine roughly 0.15 MME, hydrocodone about 1.0 MME, oxycodone approximately 1.5 MME, and hydromorphone roughly 4.0 MME. Transdermal fentanyl occupies a far higher potency tier; it is dosed in micrograms rather than milligrams, and conversion requires particular caution because of non-linear kinetics and elevated risk of accumulation.

MME calculations serve practical clinical purposes. They guide safer transitions between opioids, support rational rotation strategies, and inform structured tapering plans. Equally important, they help contextualize overdose risk when multiple opioids or sedatives are used concurrently (CDC, 2022).

Receptor pharmacology further refines risk assessment. Full agonists—morphine, heroin, methadone, and fentanyl—fully activate mu-opioid receptors. They produce analgesia and euphoria while generating dose-dependent respiratory depression that lacks a ceiling. Partial agonists such as buprenorphine activate mu receptors only partially; they deliver analgesia and reduce craving yet exhibit a ceiling effect on respiratory depression. Antagonists occupy the same receptors without activating them: naloxone rapidly displaces agonists and reverses overdose, whereas naltrexone provides sustained blockade that prevents receptor activation.

These pharmacologic distinctions translate directly into clinical practice. With full agonists, respiratory depression intensifies as dose increases, explaining the primary mechanism of fatal overdose. Buprenorphine’s ceiling effect lowers the risk of respiratory depression and stabilizes craving; its high receptor affinity allows it to displace full agonists, which can precipitate withdrawal if induction is begun too early. Naloxone reverses overdose by competitive displacement, yet its shorter half-life relative to fentanyl or methadone means patients require careful monitoring to prevent re-sedation. Naltrexone maintains mu-receptor blockade and thereby supports relapse prevention in patients who are already opioid-free; it also attenuates alcohol-induced dopaminergic reinforcement (SAMHSA, 2018; American Society of Addiction Medicine [ASAM], 2020).

Three Waves: The US Overdose Epidemic and Synthetic Surge

When I counsel patients and families, I explain the three-wave pattern of overdose mortality:

• 1999–2010: Prescription opioid sales quadrupled; overdose deaths doubled (from ~2.9 to ~6.8 per 100,000).
• 2010–2013: Heroin became cheaper; heroin overdose deaths increased (from ~1 to ~4.9 per 100,000), surpassing prescription opioids.
• 2013–present: Synthetic opioids (especially fentanyl) drove exponential increases in overdose deaths, rising by over 1,000% over five years (CDC, 2024). Non-opioid sedatives such as xylazine are now present in up to ~10% of fentanyl-related overdoses, complicating reversal (CDC, 2024; NIDA, 2023).

Public health significance:

• 2017: HHS declared opioids a public health emergency.
• Ongoing surveillance by CDC/SAMHSA guides harm reduction, naloxone distribution, and treatment expansion.

Prevalence, Demographics, and Implications

Population-level data remain essential for guiding outreach efforts and allocating clinical resources effectively. According to the Substance Abuse and Mental Health Services Administration’s National Survey on Drug Use and Health (2021), approximately 9.2 million individuals aged 12 and older reported opioid misuse in the preceding year. The large majority of this misuse involved prescription pain relievers—roughly 8.1 million people—while heroin misuse accounted for a smaller but clinically more hazardous subset of about 1.1 million individuals. The elevated per-event risk associated with heroin stems from its high potency and frequent contamination with synthetic opioids. Substantial overlap exists between the two patterns of use, with many individuals transitioning from prescription-opioid misuse to heroin.

Despite the scale of the problem, a pronounced treatment gap persists. Roughly 9 million adults are estimated to need care for opioid-use disorder. Yet, only about 2 million receive medications for opioid-use disorder (MOUD), even though robust evidence demonstrates that these medications reduce mortality. Access is unevenly distributed: individuals who do receive treatment are disproportionately White males between the ages of 35 and 49, underscoring persistent equity gaps in both availability and engagement (SAMHSA, 2023).

The human and economic costs are correspondingly severe. In 2022, approximately 82,000 people died of opioid overdose in the United States. The annual economic burden of the opioid crisis exceeds $193 billion when medical care, lost productivity, criminal-justice involvement, and premature mortality are taken into account (CDC, 2024; NIH/NIDA, 2023).

These figures carry clear clinical implications. Screening must be intensified across primary-care and specialty settings, care must be destigmatized so that patients feel safe seeking help, and pathways to MOUD must be simplified. Multidisciplinary models that integrate medical, behavioral, and supportive services improve linkage to care and help close the persistent treatment gap.

DSM-5: From “Abuse/Dependence” to Substance Use Disorder

I emphasize behavior and function rather than moral judgments. DSM-5 categorizes substance use disorder by symptoms across a mild, moderate, and severe spectrum.

Diagnostic criteria (need ≥2 within past 12 months):

• Larger amounts or longer periods than intended
• Persistent desire or unsuccessful efforts to cut down
• Excessive time spent obtaining, using, or recovering
• Cravings
• Recurrent use leading to failure in major obligations
• Continued use despite social/interpersonal problems
• Activities given up or reduced
• Use in hazardous situations
• Continued use despite physical/psychological problems
• Tolerance
• Withdrawal

Note: Tolerance and withdrawal alone do not meet criteria without at least one behavioral criterion. The focus is on functional impairment and behavioral adaptation to substance use (American Psychiatric Association [APA], 2013).

Tackling Stigma: Language, Structure, and Clinical Outcomes

Stigma functions as a tangible clinical barrier, and it must be addressed explicitly within every care pathway. Public stigma remains widespread. Many people still fail to recognize opioid-use disorder as a chronic medical condition, instead linking it primarily to criminality and therefore opposing policies that expand treatment access. Stigmatizing attitudes also tend to intensify with age, further limiting public support for evidence-based care.

Structural stigma compounds these attitudes. The legacy of the “War on Drugs,” formally declared in 1971, produced disproportionate incarceration of racial and ethnic minorities and left large numbers of individuals with limited access to treatment inside criminal-justice settings. For years, the historical X-waiver requirement for buprenorphine created an additional administrative barrier that restricted the number of clinicians able to prescribe this evidence-based medication. Organizational policies—such as mandatory drug testing for employment or housing—can further reinforce stigma by treating recovery status as a disqualifying condition rather than a medical reality.

At the individual level, stigma manifests through persistent stereotypes that portray people with opioid-use disorder as “dangerous” or “unpredictable.” These stereotypes generate prejudice expressed as moral outrage, anger, resentment, or fear, which in turn drive discriminatory actions such as coercive treatment, the withholding of care or medications, and social exclusion. Internalized stigma adds another layer: many patients experience profound shame, viewing themselves as “less than,” while some recovery communities continue to question the legitimacy of sobriety achieved with the help of medications for opioid-use disorder.

Provider bias is equally consequential. Surveys show higher rates of bias among clinicians practicing in rural settings compared with urban ones. Legal concerns surrounding opioid-use-disorder care and the lingering belief that the condition represents a moral failing further increase reluctance to prescribe medications for opioid-use disorder, thereby reducing access precisely where it is needed most.

Language itself can either perpetuate or reduce stigma. Person-first phrasing—”person with substance use disorder,” “person in recovery,” “people who use drugs,” or “people who inject drugs”—centers the individual rather than the diagnosis. In neonatal contexts, “neonatal opioid withdrawal” replaces the outdated and inaccurate term “addicted baby.” Laboratory results are more accurately described as “positive” or “negative” for a substance rather than “dirty” or “clean.” Preferred treatment terminology has shifted from “medication-assisted treatment” to “medications for opioid use disorder,” and the word “misuse” is preferred over “abuse.”

These deliberate language choices and broader stigma-reduction efforts are not merely symbolic. Evidence consistently links lower stigma to higher rates of medication uptake and retention, stronger engagement in care, and ultimately fewer overdose deaths (SAMHSA, 2023; ASAM, 2020).

Case Language Reframing: A Practical Exercise

When teaching clinical teams, one of the most practical exercises is to rewrite case notes and patient descriptions into neutral, person-first language. The contrast between common stigmatizing phrasing and carefully reframed alternatives makes the impact of word choice immediately clear.

Consider several typical examples of language that still appears in charts and conversations. A note might read “Patient reports abusing heroin IV,” or “Last used heroin after seven years clean,” or “Regularly involved with addict community.” In neonatal contexts, one still encounters the phrase “Child born addicted to heroin.” Each of these formulations carries implicit judgment and reduces a complex clinical picture to a moral failing.

The same information can be conveyed with precision and respect. “Patient reports misusing heroin IV” accurately describes the behavior without the loaded verb “abusing.” “Last heroin use one month ago after seven years of no use” replaces the ambiguous and value-laden term “clean” with a clear temporal statement. “Regularly involved with the recovery community” acknowledges social connection without the pejorative label “addict.” Finally, “Child born with neonatal opioid withdrawal; healthy now” correctly identifies the physiologic condition and updates the outcome, avoiding the inaccurate implication that a newborn is itself “addicted.”

These linguistic shifts serve several interlocking purposes. Person-first language strengthens the therapeutic alliance by signaling that the clinician sees a whole person rather than a problem. It reduces the shame and defensive reactions that often arise when patients encounter judgmental wording, thereby improving engagement and honesty. It also produces more accurate and neutral documentation that better reflects the clinical facts. Ultimately, the practice aligns everyday communication and charting with contemporary evidence-based standards for the care of people with substance-use disorders.

Motivational Interviewing: Engaging Patients with Compassion and Strategy

Motivational Interviewing (MI) forms a central pillar of our clinical approach. It is grounded in neuroscience demonstrating that substance use impairs decision-making circuits, while simultaneously affirming that meaningful change remains possible when patients are met with genuine empathy and collaboration.

The spirit of MI rests on four interlocking principles. Partnership emphasizes collaboration rather than persuasion; the clinician works alongside the patient instead of directing them. Evocation focuses on drawing out the patient’s own values, goals, and motivations rather than imposing external ones. Acceptance requires honoring autonomy, expressing empathy, and offering affirmations that recognize the patient’s strengths. Compassion sustains a consistently nonjudgmental and nonblaming stance throughout the interaction.

These principles are enacted through a sequential yet flexible process. Engaging begins with the deliberate building of rapport through active listening and genuine curiosity. Focusing follows, as the clinician and patient identify shared goals rooted in the patient’s priorities. Evoking then centers on eliciting “change talk”—the patient’s own statements about reasons and desires for change. Planning concludes the cycle by co-creating specific, realistic next steps and identifying the supports needed to carry them out.

Two complementary skill sets operationalize this process. The OARS framework provides the foundational communication tools: open-ended questions that invite elaboration, affirmations that highlight strengths and effort, reflective listening that demonstrates understanding, and summaries that organize and reinforce what has been said. The DARN-CATS sequence further guides the elicitation of change talk by exploring desire (“What do you hope our work will accomplish?”), ability (“What do you think you can change about your use?”), reasons (“Why do you want to reduce or stop?”), and need (“What needs to happen for you to feel ready?”). It then surfaces commitment (“I intend to…”), activation (“I am ready to…”), and concrete steps already taken (“I have already…”).

The Stages of Change model developed by Prochaska and DiClemente supplies an additional organizing framework. In precontemplation, the patient is not yet considering change. Contemplation involves actively weighing the advantages and disadvantages of change. Preparation is marked by concrete planning and the gathering of resources. Action is the phase of initiating change—for example, beginning buprenorphine. Maintenance is the sustained practice of the new pattern, such as remaining on medications for opioid-use disorder for a year or longer.

In everyday clinical work, language cues and behavioral indicators help the clinician identify the patient’s current stage so that interventions can be matched accordingly. When applied skillfully, Motivational Interviewing improves retention in opioid-use-disorder treatment and enhances the effectiveness of medications for opioid-use disorder (Miller & Rollnick, 2013; ASAM, 2020).

Non-Pharmacological Supports: Behavioral Therapies and Groups

Non-pharmacological supports are offered as complementary elements of care rather than as prerequisites for medical therapy. Individual counseling remains a core option and is typically provided by psychologists, social workers, or trained recovery coaches. Evidence-based modalities such as Cognitive Behavioral Therapy (CBT) and Rational Emotive Behavior Therapy (REBT) are particularly useful for helping patients develop practical coping skills, challenge unhelpful thought patterns, and strengthen motivation for sustained change.

Group-based support expands the range of available resources. SMART Recovery employs CBT- and REBT-informed tools in a structured, secular format. Traditional 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) remain widely accessible and may incorporate optional spiritual or religious components that some patients find meaningful. Secular Organizations for Sobriety (SOS) provides an alternative for individuals who prefer an explicitly non-spiritual approach. Because many of these meetings are open to the public, clinicians are encouraged to observe sessions firsthand so they can offer informed, personalized recommendations rather than generic referrals.

Research consistently shows that behavioral interventions improve coping skills, medication adherence, and relapse prevention. Group participation can further enhance outcomes for many patients; however, attendance should never function as a gatekeeper. Access to medications for opioid-use disorder must not be made contingent on participation in any particular support group (ASAM, 2020; SAMHSA, 2018).

Medications for Opioid Use Disorder: Mechanisms, Outcomes, Safety

Medications for opioid-use disorder (MOUD) are lifesaving interventions. Explaining their mechanisms clearly to patients supports understanding, reduces anxiety, and strengthens adherence.

• Methadone is a synthetic full mu-opioid agonist available only through certified Opioid Treatment Programs. It effectively reduces craving and markedly improves treatment retention, with robust evidence that it lowers mortality. Common side effects include constipation, dizziness, sedation, nausea, and sweating. More serious risks involve QTc prolongation—particularly at doses above 100 mg per day—and respiratory depression. Absolute contraindications include known allergy, acute or severe asthma, and gastrointestinal obstruction. When dosing and monitoring are carefully structured, these risks can be mitigated, making methadone especially suitable for patients who require full-agonist stabilization (ASAM, 2020; SAMHSA, 2018).
• Buprenorphine is a high-affinity partial mu agonist and kappa antagonist. Its partial agonism produces a ceiling effect on respiratory depression, allowing effective reduction of craving without the intense euphoria of full agonists and with a substantially lower risk of fatal overdose when used alone. It also displaces full agonists from the receptor because of its high binding affinity. Side effects commonly include headache, constipation, nausea, orthostatic hypotension, and, with sublingual or buccal formulations, oral hypoesthesia. Respiratory depression becomes a greater concern primarily when buprenorphine is combined with other sedatives; rare cases of hepatotoxicity have also been reported. Contraindications include hypersensitivity and severe hepatic impairment, especially with products that contain naloxone. Clinically important interactions involve benzodiazepines (increased respiratory-depression risk, though the FDA advises against withholding buprenorphine because untreated opioid-use disorder carries even higher risk of illicit use), CYP3A4 inhibitors such as erythromycin or grapefruit juice (which raise buprenorphine levels), CYP3A4 inducers such as rifampin or St. John’s wort (which lower levels), and serotonergic agents (which require monitoring for serotonin-related symptoms). The pharmacologic profile of buprenorphine makes it particularly well suited to outpatient, office-based care (ASAM, 2020; FDA, 2017; SAMHSA, 2018).
• Naloxone is a pure mu-opioid antagonist with a relatively short half-life. It is indicated for the emergency reversal of opioid overdose and is also incorporated into some buprenorphine formulations to deter intravenous misuse. By competitively displacing opioids from the receptor, naloxone rapidly restores respiration; however, because its duration of action is often shorter than that of fentanyl or methadone, emergency medical services must still be activated to prevent re-sedation. In opioid-dependent individuals, it precipitates withdrawal; in the absence of opioids, it has minimal effect. Available forms include intranasal devices (for example, NARCAN 4 mg per 0.1 mL) and injectable preparations used by emergency personnel. Dosing may be repeated every two to three minutes if there is no response, and both devices in a standard kit may be used if necessary. Community distribution of naloxone and routine co-prescribing for any patient using opioids or at elevated risk of illicit-drug contamination have been shown to reduce mortality (CDC, 2024; SAMHSA, 2018).

Naltrexone is a mu- and kappa-opioid antagonist that prevents receptor activation and also reduces alcohol-induced dopamine release. It therefore decreases craving for both opioids and alcohol and has been shown to lower rates of heavy drinking and relapse. Side effects include headache, anorexia, gastrointestinal upset, and, with the extended-release injectable form, injection-site reactions. Serious risks encompass acute hepatitis, eosinophilic pneumonia, and the potential for depression or suicidality. It is contraindicated in patients who are actively using opioids (because of the risk of precipitated withdrawal) and in those with acute hepatitis or liver failure; liver enzymes should be monitored, with particular attention when values reach or exceed three times the upper limit of normal. Formulations include the extended-release intramuscular injection (Vivitrol 380 mg administered gluteally once monthly, requiring a minimum of 21 days of opioid abstinence for faster metabolizers) and an oral tablet typically dosed at 50 mg daily. Naltrexone is most appropriate for motivated patients who are already opioid-free and offers the additional benefit of treating concurrent alcohol-use disorder when careful hepatic monitoring is maintained (ASAM, 2020; SAMHSA, 2018).

Taken together, the evidence is clear: medications for opioid-use disorder reduce all-cause and overdose mortality by as much as 50–60 percent, improve treatment retention, and decrease illicit opioid use (Sordo et al., 2017; National Academies of Sciences, Engineering, and Medicine, 2019; ASAM, 2020).

Harm Reduction: Practical Safety Measures That Save Lives

Harm reduction begins with the recognition that people will continue to use substances, and it focuses on maximizing safety and preserving dignity in the face of that reality.

A foundational component is widespread education and access to naloxone. Patients, family members, and peers are trained to recognize the signs of overdose and to administer the medication promptly. Because many synthetic opioids and long-acting agents can outlast naloxone’s effect, every training emphasizes the necessity of calling emergency medical services immediately after administration to prevent re-sedation.

• Fentanyl test strips offer another practical layer of protection. Individuals are encouraged to test heroin, cocaine, and other substances before use so that unexpected fentanyl contamination can be detected. A positive result may lead some people to forgo use altogether or to adopt safer consumption strategies.
• The Never Use Alone hotline provides real-time supervised-use support by telephone. Callers remain on the line while using; if they become unresponsive, operators can dispatch emergency responders to the location.
• Clean needle and syringe exchange programs reduce transmission of HIV and hepatitis C while simultaneously serving as low-threshold entry points for health education, vaccination, and linkage to treatment services.
• Urine drug screening, when performed in a nonjudgmental manner, functions as a safety tool rather than a punitive measure. Results can alert patients to the presence of unexpected contaminants—for example, fentanyl positivity in someone who reports using only heroin—and thereby inform more protective decision-making.
• Prescription drug monitoring programs give clinicians a coordinated view of controlled-substance prescriptions across providers. This shared awareness helps reduce unsafe polypharmacy and can identify patterns suggestive of diversion.

Across these interventions, motivational interviewing keeps the patient’s goals at the center of the conversation and strengthens engagement with harm-reduction strategies that feel realistic and acceptable at the time.

Collectively, these approaches reduce fatalities and infectious disease transmission, increase the likelihood that individuals will eventually seek formal treatment, and respect autonomy while repeatedly offering opportunities for change (CDC, 2024; SAMHSA, 2018; NIDA, 2023).

Integrative Chiropractic Care Within Medically Supervised OUD Treatment

Chronic pain frequently coexists with OUD. Pain is both a driver and a consequence of substance use patterns. Our integrative approach leverages chiropractic care to modulate pain and autonomic function under medical oversight.

My chiropractic goals in OUD-integrated care:

• Reduce nociceptive input and central sensitization to lower pain without escalating opioids.
• Improve mobility, posture, and biomechanics to decrease pain triggers and functional impairment.
• Support autonomic balance (sympathetic-parasympathetic regulation) via manual therapies that influence reflex arcs and stress responses.
• Enhance proprioception and motor control—patients with chronic pain and OUD often exhibit altered neuromuscular patterns; retraining restores functional confidence.
• Collaborate with the medical team to monitor safety, medications, and comorbidities.

Physiological underpinnings:

• Persistent nociception induces central sensitization—amplified pain perception via spinal dorsal horn wind-up and cortical reorganization. Non-pharmacological inputs (manual therapy, graded movement) can attenuate overactive nociceptive pathways and downregulate hyperexcitability via mechanoreceptor activation and inhibitory interneurons.
• Chiropractic adjustments and soft tissue therapies stimulate mechanoreceptors (A-beta fibers), enhance inhibitory gating in the dorsal horn, and may influence descending modulatory pathways (periaqueductal gray, rostral ventromedial medulla), potentially increasing endogenous opioid peptide release in controlled, non-addictive patterns.
• Autonomic modulation: Manual therapies can reduce sympathetic overactivity, which otherwise heightens pain, anxiety, and sleep disturbances. Improved parasympathetic tone fosters recovery and reduces stress-driven cravings.
• Movement rehabilitation: Graded exposure reduces kinesiophobia (fear of movement), restoring function and decreasing pain catastrophizing, thereby reducing the psychological drivers that often escalate opioid use.

Why integrate chiropractic in OUD care:

• Aligns with goals to reduce reliance on full agonist opioids.
• Addresses musculoskeletal contributors to pain that medication alone cannot resolve.
• Enhances quality of life and functional capacity, improving adherence to MOUD and behavioral interventions.
• Provides frequent therapeutic contact, offering opportunities for motivational interviewing and early detection of relapse risk.

Safety and oversight:

• Cardenas provides medical direction, reviewing comorbidities (cardiopulmonary disease, hepatic status, psychiatric conditions), medication interactions, and monitoring risks for patients on MOUD.
• We screen for red flags (e.g., neuro deficits, infection, fracture, severe cardiac disease) before manual therapies.
• We coordinate with behavioral health and primary care to manage depression, anxiety, and sleep—factors that impact pain and cravings.

Clinical observations:

• Patients with well-coordinated manual therapy and movement plans often report decreased pain scores, improved sleep, and reduced stress—enablers of sustained recovery.
• Chiropractic care can meaningfully complement buprenorphine or methadone by offering functional progress without increasing pharmacologic risk.
• Integrative functional medicine supports systemic factors (inflammation, metabolic dysregulation) that exacerbate pain and mental health symptoms, further stabilizing recovery (see my published insights and case narratives at dralexjimenez.com and my LinkedIn profile).

Functional Medicine: Addressing Root-Cause Drivers That Sustain Pain and Cravings

Functional medicine aligns naturally with chronic-care models by examining the interconnected physiological systems that influence outcomes in opioid-use disorder. Several domains receive particular attention.

• The gut-liver-brain axis is central. Dysbiosis and increased intestinal permeability can drive systemic inflammation and neuroinflammation, intensifying both pain perception and mood instability. Concurrently, hepatic function governs the metabolism of medications such as buprenorphine and naltrexone and determines overall detoxification capacity, making liver health a practical therapeutic target.
• Endocrine and hypothalamic-pituitary-adrenal (HPA) axis regulation also plays critical roles. Chronic stress elevates cortisol, and a dysregulated HPA axis contributes to anxiety, sleep disruption, and immune dysregulation—factors that heighten craving and elevate relapse risk.
• Micronutrient status and mitochondrial bioenergetics further shape resilience. Deficiencies in magnesium, omega-3 fatty acids, and other nutrients, together with impaired mitochondrial function, commonly worsen fatigue, depression, and pain, thereby undermining apatient’ss capacity to sustain recovery efforts.
• Inflammatory signaling provides another mechanistic link. Elevated pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha correlate with greater depressive symptoms and higher pain severity. Anti-inflammatory lifestyle measures can therefore produce measurable symptomatic relief.
• Sleep architecture is equally consequential. Fragmented or insufficient sleep increases vulnerability to relapse, whereas consistent sleep hygiene, circadian alignment, and regular physical activity improve both cognitive function and emotional regulation.

These physiological insights translate into concrete interventions. Nutrition counseling emphasizes anti-inflammatory dietary patterns, typically Mediterranean-style eating, with adequate protein, fiber, and omega-3 fatty acids while reducing ultra-processed foods and added sugars. Gut support may include symptom-guided probiotics or prebiotics and, when indicated, evaluation and treatment of small intestinal bacterial overgrowth or functional dyspepsia. Micronutrient assessment allows targeted correction of deficiencies—most commonly vitamin D, magnesium, and B-complex vitamins—and, when appropriate, mitochondrial support with coenzyme Q10. Stress and sleep interventions incorporate mind-body practices such as breathing exercises and gentle yoga, cognitive strategies for emotional regulation, consistent sleep-wake schedules, and reduction of evening stimulants and blue-light exposure. Movement plans begin with progressive, low-impact activity designed to rebuild physical confidence and reverse deconditioning.

Taken together, functional-medicine approaches complement medications for opioid-use disorder by stabilizing the physiological drivers of pain and mood symptoms. Patients often feel a greater sense of agency as they gain practical tools and see tangible improvements, which in turn reinforces adherence to the overall treatment plan.

Personal Injury Care and OUD: Navigating Trauma, Pain, and Medico-Legal Dynamics

After motor vehicle collisions, workplace injuries, or falls, patients may face intense pain, PTSD features, financial stress, and medico-legal complexities. These factors can intersect with opioid exposure and misuse risk.

Our approach:

• Trauma-informed care: Acknowledge fear, grief, and uncertainty; normalize stress responses; provide coping supports.
• Pain triage: Identify nociceptive, neuropathic, and central mechanisms; treat accordingly with non-opioid strategies, MOUD if OUD is present, and interventional referrals as needed.
• Documentation integrity: Medical oversight ensures accurate records for legal proceedings; PDMP checks; evidence-based guidelines.
• Functional goals: Early mobilization; graded activity; chiropractic alignment and soft tissue care to reduce acute compensatory patterns and prevent chronicity.
• Behavioral supports: Screen for depression, anxiety, and PTSD; refer for therapy; integrate MI to support engagement.

Clinical observations:

• Patients benefit from clear, coordinated plans that minimize opioid reliance and provide tangible progress markers (range of motion, pain scales, functional tasks).
• Close follow-up improves adherence and allows timely adjustments.

Integrating Internal Medicine Oversight: The Role of Dr. Maria Guadalupe Cardenas, MD

Dr. Cardenas’s oversight ensures medical safety, regulatory compliance, and quality improvement. In our clinic:

• She supervises OUD care plans, MOUD prescriptions, and management of medical comorbidities.
• She evaluates lab markers (hepatic panels for naltrexone; QTc for methadone; pregnancy tests, infectious disease screens) and integrates primary care considerations (diabetes, hypertension, COPD/asthma).
• She coordinates hospital care or specialist referrals when needed.
• She guides protocols for benzodiazepine co-use risk management, balancing FDA guidance with clinical realities.
• She supports continuous education and policy adherence for our team, ensuring alignment with SAMHSA, ASAM, and state licensing standards.

This physician-led framework legitimizes integrative methods and provides a safety net for complex cases.

Why Each Technique Fits: Clinical Reasoning in Practice

Patients and clinicians benefit from a clear understanding of why particular tools are selected and how each one contributes to a coherent treatment plan.

• Buprenorphine is chosen for initiation because it is a high-affinity partial agonist that stabilizes craving while carrying a lower risk of respiratory depression than full agonists. These properties make it especially suitable for outpatient settings, and the evidence base for improved retention and reduced mortality is strong. Induction is begun only once moderate withdrawal is present to avoid precipitated withdrawal; the dose is then carefully titrated to symptom relief, with ongoing hepatic monitoring.
• Methadone maintenance is appropriate for patients who require fuller receptor activation or who have not tolerated buprenorphine. As a full agonist delivered within a structured opioid-treatment program, it provides reliable stabilization when daily observed dosing and clinical monitoring are in place. Protocol elements include electrocardiographic assessment of the QTc interval, evaluation of potential drug interactions, reinforcement of adherence, and close coordination with the treatment program.
• Extended-release naltrexone is reserved for individuals who are already opioid-abstinent and who prefer a non-opioid, receptor-blocking strategy for relapse prevention. It offers the additional advantage of reducing alcohol craving and consumption. Before the first injection, opioid-free status is verified, baseline liver enzymes are obtained, and monthly injections are thereafter paired with counseling support, with continued hepatic surveillance.
• Naloxone co-prescribing is regarded as essential whenever any opioid exposure exists or when contamination of the illicit supply is possible. Overdose reversal with naloxone demonstrably saves lives. Patients and household members receive hands-on training, are instructed to activate emergency services after administration, and receive kits as a routine component of care.

Motivational interviewing and deliberate language shifts are employed because they increase trust, reduce treatment dropout, and strengthen self-efficacy. By eliciting change talk and supporting collaborative planning, these approaches improve adherence to every other element of the care plan.

• Chiropractic and manual therapy are integrated to address musculoskeletal pain generators and autonomic stress that frequently drive ongoing substance use. When contraindications are carefully screened and treatment is coordinated with medications for opioid-use disorder and medical oversight, progressive movement plans can safely restore function and lessen reliance on opioids.
• Functional-medicine supports target the physiological imbalances—nutritional deficiencies, sleep disruption, inflammatory signaling, and mitochondrial inefficiency—that amplify pain and mood instability. Personalized nutrition, sleep optimization, and micronutrient repletion are monitored for measurable outcomes and are coordinated with behavioral interventions so that gains in resilience reinforce overall treatment adherence.
• Harm-reduction measures meet patients at their current stage of readiness. By providing practical tools such as naloxone and fentanyl test strips, clear education, and non-punitive linkages to care, these strategies reduce fatal outcomes and infectious complications while keeping the door open for future treatment engagement.

Each intervention addresses specific physiological, behavioral, or environmental determinants of opioid-use disorder. When combined, they form a robust, patient-centered pathway designed to maximize survival and restore quality of life.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Clinical Scenarios: Applying the Model

Scenario 1 involves a patient living with chronic low-back pain who has recently transitioned from scarce street oxycodone to heroin. The individual wants help yet remains fearful of withdrawal. Care begins with motivational interviewing focused on eliciting personally meaningful goals, such as remaining present for a child’s developmental milestones. Once moderate withdrawal is evident, buprenorphine induction is initiated and carefully titrated to achieve symptom control. A naloxone kit is provided for household members. Concurrently, chiropractic management emphasizes gentle mobilizations, soft-tissue techniques, and graded stabilization exercises, paired with practical education on posture and ergonomics. Functional-medicine support includes guidance toward an anti-inflammatory dietary pattern, assessment of magnesium and vitamin D status, and structured sleep optimization. Behavioral referral addresses pain catastrophizing through cognitive-behavioral therapy and introduces SMART Recovery groups. All elements proceed under internal-medicine oversight, including hepatic panels, infectious-disease screening, and reconciliation of the prescription-drug monitoring program.

Scenario 2 concerns a patient maintained on methadone who continues to experience persistent neck pain and disrupted sleep while working full-time. Anxiety intensifies near the anniversary of the original injury. Coordination with the patient’s opioid-treatment program is established first, with particular attention to QTc interval and potential medication interactions. Chiropractic care then targets cervical mobility, thoracic extension, and scapular stabilization while incorporating techniques aimed at autonomic downregulation. A practical sleep-hygiene plan is developed alongside mindfulness strategies for managing anniversary-triggered anxiety. Harm-reduction measures are reinforced, and the household naloxone supply is updated. Functional-medicine contributions focus on nutritional support for sleep quality and inflammation reduction, along with a moderate aerobic activity program tailored to the patient’s work demands. Motivational interviewing is used throughout to reinforce language and coping strategies consistent with the maintenance stage of change.

Scenario 3 centers on a young adult with binge alcohol use and intermittent oxycodone misuse who explicitly prefers a non-opioid strategy and is willing to discontinue opioids entirely. Extended-release naltrexone is initiated with monthly intramuscular injections after baseline liver-enzyme assessment. Behavioral supports targeting alcohol reduction are introduced, including SMART Recovery participation. Chiropractic and rehabilitative care address residual shoulder pain to minimize musculoskeletal drivers of substance use. Functional nutrition is employed to stabilize energy and mood while establishing consistent sleep-wake windows. Because of the risk of fentanyl contamination in social drug environments, naloxone is co-prescribed as a standard safety measure.

Measuring Outcomes and Iterating Care

I track:

• Pain scores and functional measures (range of motion, gait analysis, functional task tolerance).
• Cravings and withdrawal symptom scores.
• MOUD adherence and retention.
• Sleep duration/quality; mood changes via validated scales when available.
• PDMP checks and urine drug screen patterns.
• Patient-reported outcomes (quality of life, ability to work, family engagement).

We adjust:

• Buprenorphine dose based on symptoms.
• Manual therapy frequency based on pain and function trajectories.
• Nutrition and micronutrient strategies based on lab data and symptomatic feedback.
• Behavioral support intensity per stage of change.

This dynamic model aligns with chronic disease management best practices and respects patient autonomy.

Policy and Access: From Waivers to Mainstream Care

With the MAT Act eliminating the X-waiver (2023), buprenorphine prescribing is more accessible for DEA-licensed clinicians. Yet barriers persist:

• Stigma and misinformation among providers and patients.
• Variability in insurance coverage and prior authorization hurdles.
• Transportation and childcare obstacles.
• Criminal justice transitions lacking continuity of MOUD.

Our clinic addresses these through:

• Education for patients and families.
• Advocacy with payers and community organizations.
• Coordination with justice reentry programs when possible.
• Telehealth follow-up for flexibility.

Safety Considerations: Complex Co-Use and Medical Risks

I prioritize safety in every plan.

• Benzodiazepines:

• • Co-use with opioids raises respiratory depression risk.
  • FDA guidance: Do not withhold buprenorphine; carefully monitor and consider benzodiazepine taper plans when appropriate and safe.

• Alcohol:

• • Synergistic sedation risks with opioids and sedatives.
  • Naltrexone may aid reduction in heavy drinking.

• Hepatic function:

• • Monitor with naltrexone; consider hepatic impairment with buprenorphine/naloxone combinations.

• Cardiac:

• • Methadone: QTc prolongation risk; ECG monitoring essential at higher doses or with interacting drugs.

• Pregnancy:

• • Buprenorphine and methadone are standard MOUD options in pregnancy; coordinate obstetric care and neonatal monitoring for withdrawal.

• Xylazine and polysubstance contamination:

• • Naloxone does not reverse xylazine; still essential for opioid reversal; EMS needed for comprehensive stabilization.

Building Therapeutic Alliance: What I Say and Why

Examples of patient-centered language:

• “You are not your diagnosis. You are a person with goals, and our job is to support you.”
• “Medications for opioid use disorder are treatment—like insulin for diabetes. They help stabilize biology so you can focus on living.”
• “Your pain is real; we will tackle it with safe, integrated methods so you don’t have to carry this alone.”
• “Let’s choose steps you feel ready for; we’ll adjust as you go.”

Rationale:

• Empathy and autonomy support enhance engagement and reduce dropout.
• Respect aligns with evidence that shame is countertherapeutic.

Our Clinic’s Multidisciplinary Logistics

Workflow:

• Intake: Medical history, substance use assessment (DSM-5), pain and function measures, labs as indicated.
• Team huddle: Dr. Cardenas reviews medical risks; I outline chiropractic and functional medicine pathway; behavioral referral options.
• Plan delivery: MI framing; written care plan; safety tools (naloxone).
• Follow-ups: Adjust MOUD dosage; progress rehab; monitor labs; track outcomes.

Documentation:

• Person-first language; neutral lab reporting.
• PDMP reconciliation; risk factor tracking.

Quality:

• Align with ASAM guidelines; update policies periodically.
• Staff training in MI and stigma reduction.

Clinical Observations: What I’ve Learned

From years of integrating chiropractic care with MOUD and medical oversight:

• Patients thrive when pain is addressed with hands-on care and structured movement; reduced pain correlates with lower cravings.
• A physician collaborator increases patient trust and improves complex medical management.
• Functional medicine elements—nutrition, sleep, stress regulation—often make the difference between coping and relapse.
• Frequent, shorter visits can sustain momentum and help detect setbacks early.
• Community resources (SMART Recovery, syringe services, naloxone training) extend our reach and safety net.

Find more of my clinical insights:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

Conclusion: A Compassionate, Evidence-Based Path Forward

Opioid-use disorder is a chronic, treatable medical condition rather than a moral failing or a permanent sentence. When medications for opioid-use disorder are combined with integrative chiropractic care, functional-medicine support, and continuous medical oversight, patients gain a realistic pathway to reclaim physical function, reduce persistent pain, and restore stability to daily life. Harm-reduction strategies protect both individuals and the wider community, while motivational interviewing ensures that every clinical decision remains centered on the patient’s own values and readiness for change.

Under the medical direction of Dr. Maria Guadalupe Cardenas, MD, our clinic has assembled a multidisciplinary team that deliberately aligns these elements into a coherent, research-informed model of care. The goal is straightforward: to lower mortality, diminish suffering, and expand the possibility of sustained recovery and improved quality of life.

We invite patients, families, and referring clinicians to engage with this approach—one that holds rigorous science and human dignity in equal regard.

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (APA, 2013).
• American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder (2020) (ASAM, 2020).
• Centers for Disease Control and Prevention. Opioid Overdose Data and Guidelines (2022–2024) (CDC, 2024).
• Food and Drug Administration. FDA Drug Safety Communication on Medication-Assisted Treatment and Benzodiazepines (2017) (FDA, 2017).
• Miller, W. R., & Rollnick, S. Motivational Interviewing: Helping People Change (3rd ed.) (Miller & Rollnick, 2013).
• National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives (2019) (NASEM, 2019).
• National Institute on Drug Abuse. Trends in Overdose Deaths and Fentanyl Contamination (2023) (NIDA, 2023).
• Sordo, L., et al. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis (BMJ, 2017).
• Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP 63) (SAMHSA, 2018).
• Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health (2021–2023) (SAMHSA, 2023).

SEO tags: opioid use disorder, buprenorphine, methadone, naltrexone, naloxone, chiropractic care, integrative medicine, functional medicine, motivational interviewing, harm reduction, DSM-5 substance use disorder, stigma reduction, overdose prevention, fentanyl, xylazine, PDMP, El Paso clinic, internal medicine oversight, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, multidisciplinary care, evidence-based treatment